{"id":"tp-40261","type":"article-newspaper","title":"Amgen Reports 58% Lower Death Hazard in Lung Cancer Trial","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/40261","datePublished":"2026-10-24T19:26:21.000Z","dateModified":"2026-10-24T19:26:21.000Z","language":"en","abstract":"Median overall survival was 21.1 months with tarlatamab and durvalumab, compared with 12.7 months with durvalumab alone. The trial tested the combination as maintenance therapy after initial treatment.","section":"Business","references":[]}